Skip to main navigation
  • News
  • Alerts
  • Careers
  • Contact
Cidara Therapeutics, Inc.Cidara Therapeutics, Inc.
  • About
    • About Cidara
    • Management Team
    • Board of Directors
    • Partnership Inquiries
    • Careers
  • Pipeline
  • Rezafungin
    • Overview
    • Treatment
    • Prophylaxis
  • Cloudbreak
    • Overview
    • Antiviral
    • Antibacterial
  • Publications
    • Rezafungin for IFIs
    • Rezafungin – Other
    • Cloudbreak
  • Investors

    Secondary Investor Relations

    • Overview
    • Presentations
    • Financials
    • Stock Information
    • Corporate Governance
    • News & Events
    • Analyst Coverage
    • Shareholder Services
Press enter to begin your search
  • Home
  • About
  • Drug Candidates
    • Pipeline
    • CD101 IV
    • CD101 Topical
    • C001
    • Publications
  • Cloudbreak
  • Opportunity
    • Systemic Fungal Infections
    • Systemic Candida Infections
    • Recurrent Vulvovaginal Candidiasis
    • Invasive Aspergillosis
  • Investors

    Secondary Investor Relations

    • Overview
    • Presentations
    • Financials
    • Stock Information
    • Corporate Governance
    • News & Events
    • Analyst Coverage
    • Shareholder Services
  • Contact

SC 13G/A

SEC Filings

Document Details

Form
SC 13G/A
Filing Date
02/11/19
Document Date
02/11/19
Form Description
An amendment to the SC 13G filing
Filing Group
3,4,5
Company
Cidara Therapeutics, Inc.
Issuer
Cidara Therapeutics, Inc.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

NAVIGATION

  • Overview
  • Financials
    • SEC Filings
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
  • Corporate Governance
    • Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
  • News & Events
    • News Releases
    • Event Calendar
    • Past Events
    • Presentations
  • Analyst Coverage
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • Investor Contact

Tool Kit

Print Page Print Page
RSS Feeds RSS Feeds
E-mail Alerts E-mail Alerts
Get Important News and Updates by Email Subscribe

About Cidara

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives and immunotherapies that have the potential to transform the standard of care and save or improve patients' lives.
Learn more >>

Recent News

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
February 5, 2019
Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
December 3, 2018
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
November 27, 2018

Navigation

Secondary Investor Relations

  • Overview
  • Presentations
  • Financials
  • Stock Information
  • Corporate Governance
  • News & Events
  • Analyst Coverage
  • Shareholder Services

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Tel: (858) 752-6170
Email: info@cidara.com

© 2019 Cidara Therapeutics, Inc. | Terms of Use | Privacy Policy

Quick Links

Secondary Investor Relations

  • Overview
  • Presentations
  • Financials
  • Stock Information
  • Corporate Governance
  • News & Events
  • Analyst Coverage
  • Shareholder Services

Tweets by @CidaraThera